Novozymes Biopharma

EpiVax, Inc. is pleased to announce a new Collaborative Research Agreement with Novozymes Biopharma. The collaboration will enable EpiVax to rapidly advance its Tregitope immune-modulating technology as a potential treatment for autoimmune diseases. When used as a buffering agent, albumin has excellent safety and pharmacokinetic profiles. Fusing Tregitopes to Novozymes’ proven albumin-based half-life extension platform will create a safe and effective vehicle for the application of Tregitopes to multiple problems in the areas of autoimmunity, transplantation, and allergy.

Stage: Research

Applications: T1D, autoimmunity, transplantation, MS, allergy, IBS, CPID, IBD

Related PR:

http://www.prnewswire.com/news-releases/epivax-novozymes-tregitope-albumin-fusion-moves-paradigm-shifting-treatment-for-diabetes-closer-to-clinical-trials-190832031.html

http://www.in-pharmatechnologist.com/Drug-Delivery/EpiVax-says-Novozymes-Collaboration-has-3bn-Potential